<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112117</article-id><article-id pub-id-type="publisher-id">ACM-40752</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_58587992.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  川崎病冠脉损害的干细胞治疗研究进展
  Research Progress of Stem Cell Therapy for Coronary Artery Damage in Kawasaki Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>万</surname><given-names>萱</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>建英</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>严</surname><given-names>晓华</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>西嫔</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>菊艳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>思琼</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>成</surname><given-names>钧</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>成</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>焦</surname><given-names>富勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>西北妇女儿童医院儿科，陕西 西安</addr-line></aff><aff id="aff4"><addr-line>西安北车医院儿科，陕西 西安</addr-line></aff><aff id="aff2"><addr-line>陕西省人民医院儿童病院，陕西 西安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>826</fpage><lpage>830</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    川崎病是一种具有明显季节性和区域流行性的疾病，好发于5岁以下儿童，表现为急性自限性的全身性血管炎，累及中小动脉，特别是冠状动脉病变。目前发病呈增高趋势，大约15%~25%未经系统治疗的儿童最终发展成冠状动脉损害，成为发达国家儿童获得性心脏病的最常见原因。目前干细胞治疗小鼠川崎病模型所致的冠脉损害取得重要进展，现就干细胞治疗川崎病冠脉损害的形成进行简要综述。
    Kawasaki Disease (KD) is an acute, self-limited systemic vasculitis that affects the middle and small arteries, especially the coronary arteries. The incidence is currently on the rise, with about 15 to 25 per cent of children without systemic disease eventually developed coronary artery damage, becoming the most common cause of child-acquired heart disease in the countries where it occurs. At present, stem cell therapy for Kawasaki Disease in mice has made important progress. This article reviews the formation of stem cell therapy for Kawasaki disease. 
  
 
</p></abstract><kwd-group><kwd>川崎病，冠脉损害，干细胞, Kawasaki Disease</kwd><kwd> Coronary Artery Lesion</kwd><kwd> Stem Cell</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>川崎病是一种具有明显季节性和区域流行性的疾病，好发于5岁以下儿童，表现为急性自限性的全身性血管炎，累及中小动脉，特别是冠状动脉病变。目前发病呈增高趋势，大约15%~25%未经系统治疗的儿童最终发展成冠状动脉损害，成为发达国家儿童获得性心脏病的最常见原因。目前干细胞治疗小鼠川崎病模型所致的冠脉损害取得重要进展，现就干细胞治疗川崎病冠脉损害的形成进行简要综述。</p></sec><sec id="s2"><title>关键词</title><p>川崎病，冠脉损害，干细胞</p></sec><sec id="s3"><title>Research Progress of Stem Cell Therapy for Coronary Artery Damage in Kawasaki Disease<sup> </sup></title><p>Xuan Wan<sup>1</sup>, Jianying Feng<sup>1</sup>, Xiaohua Yan<sup>1</sup>, Xipin Zhang<sup>1</sup>, Juyan Wang<sup>1</sup>, Xiaohong Li<sup>1</sup>, Siqiong Li<sup>1</sup>, Jun Cheng<sup>2</sup>, Cheng Xiao<sup>3</sup>, Fuyong Jiao<sup>1*</sup></p><p>1Shaanxi Provincial People’s Hospital Children’s Hospital, Xi’an Shaanxi</p><p><sup>2</sup>Department of Pediatrics, Northwest Women’s and Children’s Hospital, Xi’an Shaanxi</p><p><sup>3</sup>Department of Pediatrics, Xi’an Bei Che Hospital, Xi’an Shaanxi</p><p><img src="//html.hanspub.org/file/56-1571945x4_hanspub.png" /></p><p>Received: Jan. 25<sup>th</sup>, 2021; accepted: Feb. 9<sup>th</sup>, 2021; published: Feb. 26<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/56-1571945x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Kawasaki Disease (KD) is an acute, self-limited systemic vasculitis that affects the middle and small arteries, especially the coronary arteries. The incidence is currently on the rise, with about 15 to 25 per cent of children without systemic disease eventually developed coronary artery damage, becoming the most common cause of child-acquired heart disease in the countries where it occurs. At present, stem cell therapy for Kawasaki Disease in mice has made important progress. This article reviews the formation of stem cell therapy for Kawasaki disease.</p><p>Keywords:Kawasaki Disease, Coronary Artery Lesion, Stem Cell</p><disp-formula id="hanspub.40752-formula83"><graphic xlink:href="//html.hanspub.org/file/56-1571945x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/56-1571945x8_hanspub.png" /> <img src="//html.hanspub.org/file/56-1571945x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 前言</title><p>川崎病(Kawasaki disease, KD)是自身免疫系统疾病，又称皮肤粘膜淋巴结综合征，1967年由儿科医生川崎富作首次在日本报道，多发生于五岁以下儿童，其主要是一种以全身中、小动脉炎性病变为主要病理变化的急性发热性疾病和全身性血管炎 [<xref ref-type="bibr" rid="hanspub.40752-ref1">1</xref>]。多侵犯心脏冠状动脉而引起严重的并发症。川崎病冠脉损害(coronary artery lesion, CAL)是严重的并发症，有心肌梗塞及猝死的风险，成为发达国家儿童获得性心脏病的首要治病因素。高达15%~20%的川崎病患者对大剂量静脉注射免疫球蛋白治疗没有反应，这些患者的冠状动脉瘤发生率明显增加 [<xref ref-type="bibr" rid="hanspub.40752-ref2">2</xref>]。</p></sec><sec id="s6"><title>2. 川崎病病因及发病机制</title><p>到目前为止，学者们对川崎病的发病原因及发病机制尚不十分清楚，但是通过近半个世纪的研究支持遗传因素在其发生及发展中起关键作用，并出现两大学说：感染学说及免疫学说。川崎病是一种致血管炎症性改变的自限性疾病，好发于东亚人群及冬春季，与其他感染性疾病的临床表现有重叠 [<xref ref-type="bibr" rid="hanspub.40752-ref3">3</xref>]，其临床生化指标，如白细胞/CRP增高及血沉增快，足以证明其基础病变为炎性细胞所致。川崎病急性发病期释放大量的炎性细胞因子，激活免疫细胞以后，能使活化的免疫细胞释放大量的炎性细胞因子 [<xref ref-type="bibr" rid="hanspub.40752-ref4">4</xref>]，呈恶性循环，形成瀑布反应，使机体失去对炎性反应的控制，造成内皮损伤。其次大量的肿瘤坏死因子产生，损害血管内皮细胞，造成内皮通透性增加，继而血管内皮细胞释放趋化因子，使免疫细胞向受损的血管表面聚集。肿瘤坏死细胞减少了内皮祖细胞数量，从而减低了对受损内皮细胞的修复作用，导致冠脉损害。在川崎病急性期内，机体大量释放白细胞介素，白细胞介素使细胞发生毒性作用，抑制P53基因表达，使淋巴细胞凋亡减少，持续产生更多的炎性因子和黏附分子，介导血管内皮细胞损伤 [<xref ref-type="bibr" rid="hanspub.40752-ref5">5</xref>]。T细胞异常活化是川崎病免疫系统激活导致血管免疫损伤的始动环节和关节步骤 [<xref ref-type="bibr" rid="hanspub.40752-ref6">6</xref>]。大量的T细胞使机体呈免疫活化状态，活化的T细胞作用于体液免疫，诱发血管发生炎性反应。血管内皮生长因子(Vascular dendothelial growth factor, VEGF)可导致血管通透性增高，川崎病患者血液中可检测到大量的血管内皮生长因子，血管VEGF促进白细胞聚集到冠脉炎症部位进行刺激，活化的外周血单核细胞趋化到内皮损伤部位，导致局部产生VEGF，参与冠脉血管壁的损害。通过饶晓红 [<xref ref-type="bibr" rid="hanspub.40752-ref7">7</xref>] 等人的研究，血小板参与川崎病血管损害，血小板增多及活化增强后，在受损的冠脉引起血栓形成，内膜增厚，并且其释放多种血管收缩素及凝血物质，导致心肌功能受损，增加高凝状态。目前，国内外对ITPKC/CASP3/ TGF-S/BLK/CD40/FCGR2A等研究较多，表明众多基因参与川崎病的发生及CAL发展过程 [<xref ref-type="bibr" rid="hanspub.40752-ref8">8</xref>]。总之，KD病变机制是一个复杂的过程，但研究表示其是免疫细胞异常活化及各种细胞因子的大量释放，导致血管内皮损害及功能障碍。</p></sec><sec id="s7"><title>3. 川崎病冠脉损害的病理基础</title><p>美国Lehman等 [<xref ref-type="bibr" rid="hanspub.40752-ref9">9</xref>] 通过提取乳酸菌胞壁取物(lactobacillus casei cell wall extract, LCWE)诱发冠状动脉炎模型，通过其病理切片显示心脏组织可见血管壁增粗且周围有炎症细胞浸润，可出现斑块。LCWE诱导的川崎病血管炎的特征是主动脉根部炎性细胞浸润，冠状动脉发生坏死动脉炎，然后由于LMP导致管腔堵塞，导致冠状动脉完全狭窄 [<xref ref-type="bibr" rid="hanspub.40752-ref10">10</xref>]。Philip [<xref ref-type="bibr" rid="hanspub.40752-ref11">11</xref>] 等于2004年通过猪模型发现小猪心脏冠脉不同扩张，病理学见内层弹力膜断裂内膜增生改变，血管周围炎性浸润等。学者们通过对患儿的临床数据分析及观察，结合大量的川崎病动物模型的理论研究基础及临床研究提高对川崎病诱发冠脉损害的认识。其表明川崎病是中小血管的炎症，长期的血管炎症存在最终导致冠状动脉粥样硬化。冠状动脉血管壁增厚，主干内径增宽，内膜增厚，瓣膜及心房内膜轻度肿胀，中性粒细胞散在浸润，冠状动脉管腔扩张及心肌细胞坏死溶解，局部纤维接替组织增生伴钙盐沉积。心脏外膜间质水肿，可见少量淋巴细胞浸润及纤维结缔组织弥漫增生。血管肌层被破坏，外膜可见局灶性纤维素样坏死及不同程度纤维化。管腔内可见白色血栓形成。严重持续性的冠脉血栓形成内皮细胞损伤及心肌细胞坏死，造成心脏不可逆性改变。</p></sec><sec id="s8"><title>4. 干细胞治疗的机制及效果</title><p>干细胞具有独特的生物学特性，无限的或永生的自我更新能力，其功能是维持及控制细胞再生，具有扩增能力和限制分化潜能。从功能上讲，干细胞具有多项分化潜能及自我更新能力，从而修复坏死或受损的组织。通过感染学说，只要能控制或减弱川崎病所致的炎症反应，就能使川崎病得到控制或康复，因此需要一种治疗措施能够抑制或阻断严重反应。干细胞可促进组织功能性再生修复外，还有广泛的免疫调节及抗纤维化活性的作用 [<xref ref-type="bibr" rid="hanspub.40752-ref12">12</xref>]。组织内巨噬细胞有参与炎性损伤抗炎和组织修复的多重作用，心肌梗死早期以M1性巨噬细胞为主，M1型巨噬细胞通过吞噬溶解及消化坏死心肌组织，同时导致心肌损伤 [<xref ref-type="bibr" rid="hanspub.40752-ref13">13</xref>]。M2型巨噬细胞在急性心肌梗死后期参与抗炎症反应，参与促进心脏修复效应。研究表明，干细胞移植可显著增加心肌梗塞区域M2型巨噬细胞的浸润，减少纤维化，增加血管生成，改善心脏功能。干细胞治疗心肌梗死小鼠模型研究发现，治疗一周后，心肌细胞内M1型数量较少，M2型增加，残存心肌细胞较多，淋巴细胞浸润减少，心肌细胞凋亡指数和心肌胶原沉积降低 [<xref ref-type="bibr" rid="hanspub.40752-ref14">14</xref>]。Peng Y [<xref ref-type="bibr" rid="hanspub.40752-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40752-ref15">15</xref>] 等研究表明干细胞通过调整炎症反应，降低炎性因子的表达，提高抗炎因子的表达，避免过度的炎症反应和炎症导致的组织损伤。间充质干细胞来源的外泌体可增强心肌梗死模型心肌组织中巨噬细胞M2极化效应，抑制心肌组织炎症和心肌细胞凋亡 [<xref ref-type="bibr" rid="hanspub.40752-ref16">16</xref>]。炎症反应中炎症性损伤组织向促组织修复转折的过程，是巨噬细胞M1型向M2型转化所诱导，间充质干细胞的注射诱导大量巨噬细胞M1向M2转化，从而减少川崎病的炎症反应，促进受川崎病受损心脏组织的修复。并且在《Science Translational Medicine》上发表的文献显示 [<xref ref-type="bibr" rid="hanspub.40752-ref17">17</xref>]，日本研究团队启动了心肌球来源细胞(CDC)治疗扩张型心肌病的临床试验，共涉及到5名儿童患者。在注射心肌球来源细胞一年后，患者没有出现严重副作用，且心脏功能有改善的迹象。</p><p>干细胞具有自我复制更新能力，能够有效修复损害的组织或器官 [<xref ref-type="bibr" rid="hanspub.40752-ref18">18</xref>]。干细胞是一类相对特殊的细胞该类细胞取材比较方便，且不涉及伦理等诸多问题 [<xref ref-type="bibr" rid="hanspub.40752-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.40752-ref20">20</xref>]。干细胞具有归巢性，能够作为载体工具定向运送生物制剂，从而实现相关疾病的治疗。Zhao L [<xref ref-type="bibr" rid="hanspub.40752-ref21">21</xref>] 等人通过研究证明：干细胞DNA携带的一些决定肌系分化的基因点，从而促进干细胞向心肌细胞分化。通过动物实验研究显示，应用干细胞治疗受损的心肌细胞，能够有效改善心肌供血情况，提高机体心脏功能 [<xref ref-type="bibr" rid="hanspub.40752-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.40752-ref23">23</xref>]。人脐带间充质干细胞能够向内皮细胞心肌细胞分化，加之其来源广泛免疫反应少，其具有应用于治疗川崎病造成的冠脉损害的作用。对动物模型注射干细胞后，血管冠状动脉主干内径减少，大量的淋巴细胞及嗜酸性粒细胞单核细胞浸润，未见明显的血管炎性反应及其损伤改变。干细胞可以成功分化为血管内皮细胞及部分心肌细胞，修复被川崎病所受损的心脏组织。</p></sec><sec id="s9"><title>5. 小结与展望</title><p>川崎病的传统治疗是注射丙种球蛋白或口服阿司匹林。但2004年美国心脏病学会指南指出，发热五天内应用丙种球蛋白不能降低冠脉损害的发生率，并且有发生耐药性的风险；另外丙种球蛋白价格昂贵，对患儿家庭来说增加花费。干细胞对川崎病所致的冠脉损害的再生和修复具有关键作用，提供一种新的治疗方法和思路，摆脱传统治疗的局限性，有望成功阻止CAL的发生，改善川崎病患者的预后。然而其面临不少难题，干细胞治疗冠脉损害仍处于研究阶段，干细胞提取的安全性和有效性等有待进一步研究及解决。但是通过不懈的努力，干细胞治疗将成为治疗冠脉损害更加有效的新途径。</p></sec><sec id="s10"><title>文章引用</title><p>万 萱,冯建英,严晓华,张西嫔,王菊艳,李晓红,李思琼,成 钧,肖 成,焦富勇. 川崎病冠脉损害的干细胞治疗研究进展Research Progress of Stem Cell Therapy for Coronary Artery Damage in Kawasaki Disease[J]. 临床医学进展, 2021, 11(02): 826-830. https://doi.org/10.12677/ACM.2021.112117</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40752-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Newburger, J.W., Takahashi, M. and Burns, J.C. (2016) Kawasaki Disease. Journal of the American College of Cardiology, 67, 1738-1749. https://doi.org/10.1016/j.jacc.2015.12.073</mixed-citation></ref><ref id="hanspub.40752-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Magali, N.R. and Moshe, A. (2020) Kawasaki Disease: Pathophysiology and Insights from Mouse Models. Nature Reviews Rheumatology, 16, 391-405. https://doi.org/10.1038/s41584-020-0426-0</mixed-citation></ref><ref id="hanspub.40752-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jiao, F.Y., Yan, X.H. and Wu, X.F. (2016) The Xi’an Experience of Kawasaki Disease—Lessons Learnt over 5 Years. The Indian Journal of Pediatrics, 83, 1195-1196. https://doi.org/10.1007/s12098-016-2100-8</mixed-citation></ref><ref id="hanspub.40752-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Yokota, S., Kikuchi, M., Nozawa, T., et al. (2015) Pathogenesis of Systemic Inflammatory Disease in Childhood: Lessons from Clinical Trials of Anti-Cytokine Monoclonal Antibodies for Kawasaki Disease, Systemic Onset Juvenile Idiopathic Arthritis and Cryopyrin-Associated Periodic Fever Syndrome. Modern Rheumatology, 25, 1-10.  
https://doi.org/10.3109/14397595.2014.902747</mixed-citation></ref><ref id="hanspub.40752-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Jiao, F.Y., Wang, J.Y., Feng, Y.J., Zhang, S., He, G.T. and Li, X.H. (2020) Clinical Analysis of Occurrence of Coronary Artery Aneurysm in 426 Children with Kawasaki Disease. Annals of Pediatric Research, 4, 6-8.</mixed-citation></ref><ref id="hanspub.40752-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">叶贝. 川崎病病因及发病机制的研究进展[J]. 儿科药学杂志, 2012, 18(4): 49-52.</mixed-citation></ref><ref id="hanspub.40752-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">饶晓红, 童文娟, 陈丁丁. 川崎病并发感染患儿Treg/Th17细胞免疫功能的变化及临床意义[J]. 中国医药导报, 2020, 17(5): 91-94.</mixed-citation></ref><ref id="hanspub.40752-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">刘亮, 田执梁. 川崎病相关易感基因研究进展[J]. 中国生育健康杂志, 2021, 32(1): 98-101.</mixed-citation></ref><ref id="hanspub.40752-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lehman, T.J., Allen, J.B., Plotz, P.H., et al. (1983) Polyarthritis in Rats Following the Systemic Injection of Lactobacillus casei Cell Walls in Aqueous Suspension. Arthritis &amp; Rheumatology, 26, 1259-1265.  
https://doi.org/10.1002/art.1780261013</mixed-citation></ref><ref id="hanspub.40752-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lehman, T.J., Walker, S.M., Mahnovski, V., et al. (1985) Coronary Arteritis in Mice Following the Systemic Injection of Group B Lactobacillus casei Cell Walls in Aqueous Suspension. Arthritis &amp; Rheumatology, 28, 652-659.  
https://doi.org/10.1002/art.1780280609</mixed-citation></ref><ref id="hanspub.40752-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Philip, S., Lee, W., Liu, S., et al. (2004) A Swine Model of Horse Serum-Induced Coronary Vasculitis: An Implication for Kawasaki Disease. Pediatric Research, 55, 211-219. https://doi.org/10.1203/01.PDR.0000104151.26375.E5</mixed-citation></ref><ref id="hanspub.40752-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Yan, W., Abu-El-Rub, E., Saravanan, S., et al. (2019) Inflammation in Myocardial Injury: Mesenchymal Stem Cells as Potential Immunomodulators. American Journal of Physiology—Heart and Circulatory Physiology, 317, H213-H225.  
https://doi.org/10.1152/ajpheart.00065.2019</mixed-citation></ref><ref id="hanspub.40752-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Yap, J., Cabrera-Fuentes, H.A., Irei, J., et al. (2019) Role of Macrophages in Cardioprotection. International Journal of Molecular Sciences, 20, 2472. https://doi.org/10.3390/ijms20102474</mixed-citation></ref><ref id="hanspub.40752-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Peng, Y., Chen, B.Q., Zhao, J.L., et al. (2019) Effect of Intravenous Transplantation of hUCB-MSCs on M1/M2 Subtype Conversion in Monocyte/Macrophages of AMI Mice. Biomedicine &amp; Pharmacotherapy, 11, 624-630.  
https://doi.org/10.1016/j.biopha.2018.12.095</mixed-citation></ref><ref id="hanspub.40752-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Peng, Y., Pan, W., Ou, Y., et al. (2016) Extracardiac-Lodged Mesenchymal Stromal Cells Propel an Inflammatory Response against Myocardial Infarction via Paracrine Effects. Cell Transplantation, 25, 929-935.  
https://doi.org/10.3727/096368915X689758</mixed-citation></ref><ref id="hanspub.40752-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Xu, R., Zhang, F., Liu, N., et al. (2019) Exosomes Derived from Pro-Inflammatory Bone Marrow-Derived Mesenchymal Stem Cells Reduce Inflammation and Myocardial Injury via Mediating Macrophage Polarization. Journal of Cellular and Molecular Medicine, 23, 7617-7631. https://doi.org/10.1111/jcmm.14635</mixed-citation></ref><ref id="hanspub.40752-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Hirai, K., et al. (2020) Cardiosphere-Derived Exosomal microRNAs for Myocardial Repair in Pediatric Dilated Cardiomyopathy. Science Translational Medicine, 12, eabb3336. https://doi.org/10.1126/scitranslmed.abb3336</mixed-citation></ref><ref id="hanspub.40752-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">袁肇凯, 黄献平, 李勇华, 等. 养心通脉有效部位方动员骨髓间充质干细胞归巢大鼠心肌梗塞的实验研究[J]. 中华中医药杂志, 2012, 23(1): 115-118.</mixed-citation></ref><ref id="hanspub.40752-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Chartrel, N., Alonzeau, J., Alexadre, D., et al. (2011) The RF Amide Neuropeptide 26RFa and Its Role in the Control of Neuroendocrine Function. Frontiers in Neuroendocrinology, 32, 387-397.  
https://doi.org/10.1016/j.yfrne.2011.04.001</mixed-citation></ref><ref id="hanspub.40752-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ukena, K., Tachibana, T., Iwakoshi-Ukena, E., et al. (2010) Identification, Localization, and Function of a Novel Avian Hypothalamic Neuropeptide 26RFa and Its Cognate Receptor, G-Protein-Coupled Rece-103. Endocrinology, 151, 2255-2264. https://doi.org/10.1210/en.2009-1478</mixed-citation></ref><ref id="hanspub.40752-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, L., Liu, L., Wu, Z., et al. (2012) Effects of Micropitted/Nanotubular Titania Topographies on Bone Mesenchymal Stem Cell Osteogenic Differentiation. Biomaterials, 33, 2629-2642.  
https://doi.org/10.1016/j.biomaterials.2011.12.024</mixed-citation></ref><ref id="hanspub.40752-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, J., Wan, Y., Chi, J., et al. (2012) The Active Principle Region of Buyang Huanwu Decoction Induced Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells into Neural-Like Cells: Superior Effects over Original Formula of Buyang Huanwu Decoction. Neural Regeneration Research, 7, 261-267.</mixed-citation></ref><ref id="hanspub.40752-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">郑景辉, 李勇华, 王丽萍, 等. 不同血清微环境对大鼠骨髓间充质干细胞体外培养的影响[J]. 中国组织工程研究与临床康复, 2010, 14(14): 2497-2502.</mixed-citation></ref></ref-list></back></article>